Shanghai S.E.
07/02/2025
5-day change
1st Jan Change
27.10 CNY
+0.59%
-1.74%
-6.81%
Jumpcan Pharma's Unit Gets Nod for Roxadustat Capsules' Registration
January 14, 2025 at 09:44 am IST
Jumpcan Pharma's Unit Gets Nod for Roxadustat Capsules' Registration
14/01
MT
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 23, 2024.
04/01
CI
Hubei Jumpcan Pharmaceutical Gets China Approval for Antibiotics
13/12
MT
Jumpcan Pharmaceutical Unit's Two Drugs Added to National Insurance Catalog
03/12
MT
Hubei Jumpcan Pharmaceutical's Q3 Profit Slides 7%; Shares Rise 4%
28/24/28
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
25/24/25
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 23, 2024.
01/24/01
CI
Jumpcan Pharmaceutical Gets China Nod for Anti-Stomach Ulcer Tablets
04/24/04
MT
Jumpcan Pharmaceutical's H1 Attributable Profit Stays Flat as Operating Income Falls 13%; Shares Slide 10%
26/24/26
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
23/24/23
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.
23/24/23
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
22/24/22
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
05/24/05
CI
Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 4, 2023, has closed with 1,051,700 shares, representing 0.11% for CNY 30.12 million.
03/24/03
CI
Hubei Jumpcan Pharmaceutical Obtains Drug Registration for Antibiotic Injection; Shares Down 3%
27/24/27
MT
Hubei Jumpcan Pharmaceutical Gets Drug Registration Certificate for Allergy Drug; Shares Slide 3%
20/24/20
MT
Jumpcan Pharmaceutical Adjusts Repurchase Price Cap After Annual Share Distribution
11/24/11
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
19/24/19
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
09/24/09
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
03/24/03
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
03/24/03
CI
Jumpcan Pharma Registers Two New Drugs
02/23/02
MT
Hubei Jumpcan Pharma’s Q3 Profit Jumps 4.8%, Revenue Falls 6%
23/23/23
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
22/23/22
CI
Nanjing Zenshine Pharmaceuticals Co., Ltd. announced that it has received CNY 100 million in funding from Hubei Jumpcan Pharmaceutical Co., Ltd., Kunlun Capital, Zhejiang Saizhi Bole Equity Investment Management Co., Ltd, Zhongshan Zhonghui Investment Group Co.,ltd.
13/23/13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
600566: Dynamic Chart
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets.
More about the company
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Buy
